You are here

Hormone Therapy Patch Approved for the Prevention of Postmenopausal Osteoporosis

Schering AG, Germany (FSE: SCH, NYSE: SHR) announced today that the Food and Drug Administration (FDA) has approved the hormone therapy patch, Climara Pro (estradiol/levonorgestrel transdermal system), for the prevention of postmenopausal osteoporosis in the U.S.

Climara Pro was approved by the FDA in November 2003 as a treatment for moderate to severe vasomotor symptoms such as hot flashes and night sweats associated with menopause. Climara Pro® is the only combination once-a-week patch approved for the prevention of postmenopausal osteoporosis and the relief of moderate to severe vasomotor symptoms associated with menopause.

“Climara Pro offers an innovative treatment option for menopausal symptoms and helps to maintain women’s health,” said Philip Smits, M.D., Head of Gynecology&Andrology at Schering AG. “The approval for osteoporosis prevention supports our position in the field of menopause management. Schering is committed to providing the best care in this field.”

The transdermal technology of Climara Pro® allows for week-long continuous delivery of the hormone estradiol (0.045 mg/day), the same estrogen made by the ovaries prior to menopause, combined with levonorgestrel (0.015 mg/day) which helps protect the endometrium. Climara Pro® delivers the hormones through a thin, translucent patch that is easily affixed to the skin and is virtually invisible after being applied.

Source: Schering AG

Recent Headlines

WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs